Herein, we report a 30-year-old male case treated with infliximab and suffered from isolated testicular tuberculosis.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Infliximab is an inhibitory of tumor necrosis factor-alpha which is used successfully for the treatment of inflammatory bowel disease and rheumatic disease.
📊
Key Findings & Data:It has various side effects including injection-induced reactions, immunosuppression, demyelinating diseases, and cardiac effects.
💡
Conclusion & Impact:Herein, we report a 30-year-old male case treated with infliximab and suffered from isolated testicular tuberculosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Infliximab is an inhibitory of tumor necrosis factor-alpha which is used successfully for the treatment of inflammatory bowel disease and rheumatic disease. It has various side effects including injection-induced reactions, immunosuppression, demyelinating diseases, and cardiac effects. One of the most serious side effects is tuberculosis. In particular, the immunosuppressant drugs have a high risk of reactivating latent tuberculosis infection. Its activation probably may occur as an extra-pulmonary and, occasionally, may result in an unusual infection. Herein, we report a 30-year-old male case treated with infliximab and suffered from isolated testicular tuberculosis.
🔖
Cite This Article
NAYİMOĞLU, M., SARIFAKIOĞLU, B., USTAÖMER, K., AKGÜL, M., ARSLAN, A. İ. (2021). A rare localization of tuberculosis under infliximab treatment: Testicular involvement. Turkish journal of physical medicine and rehabilitation, Cilt: 67 - Sayı: 3, 374–377. https://ajindex.com/articles/408566
Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005;44:714-20
Beenhouwer D, Wallis R, Broder M, Furst DE. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol 2004;31:1888-92
PAY S. Romatizmal Hastalıklarda Anti-TNF ilaç kullanımı. Türkiye Klinikleri Tıp Bilimleri Dergisi 2006;26:430-40
Drudi FM, Laghi A, Iannicelli E, Di Nardo R, Occhiato R, Poggi R, et al. Tubercular epididymitis and orchitis: US patterns. Eur Radiol 1997;7:1076-8
Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(5 Suppl1):34-8
Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-94
Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5
Hane J, Duffey B, Kaiser R, Walker PF, Alpern JD. Case report: Epididymo-orchitis due to mycobacterium tuberculosis. Am J Trop Med Hyg 2019;101:1070-2
Agbodande AK, Dodo RL, Issa A, Adjadohoun S, Azon- Kouanou A, Wanvoegbe AF, et al. Rare location of tuberculosis: endometrial tuberculosis. Pan Afr Med J 2019;33:45
Garbyal RS, Gupta P, Kumar S; Anshu. Diagnosis of isolated tuberculous orchitis by fine-needle aspiration cytology. Diagn Cytopathol 2006;34:698-700
Shugaba AI, Rabiu AM, Uzokwe C, Matthew RM. Tuberculosis of the testis: a case report. Clin Med Insights Case Rep 2012;5:169-72
Salvador R, Vilana R, Bargalló X, Araque X, Nicolau C. Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: sonographic findings. J Ultrasound Med 2007;26:671-4
Viswaroop BS, Kekre N, Gopalakrishnan G. Isolated tuberculous epididymitis: a review of forty cases. J Postgrad Med 2005;51:109-11